Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00519142

Public ClinicalTrials.gov record NCT00519142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.

Study identification

NCT ID
NCT00519142
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Elixir Pharmaceuticals
Industry
Enrollment
367 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 2007 (Type not available)
Primary completion
Oct 2008 (Actual)
Completion
Oct 2008 (Actual)
Last update posted
Sep 17, 2009

2007 – 2008

United States locations

U.S. sites
57
U.S. states
21
U.S. cities
57
Facility City State ZIP Site status
Elixir Study Site Glendale Arizona — —
Elixir Study Site Greenbrae California — —
Elixir Study Site La Jolla California — —
Elixir Study Site Los Angeles California — —
Elixir Study Site Los Gatos California — —
Elixir Study Site(s) Oakland Area California — —
Elixir Study Site Orange California — —
Elixir Study Site West Hills California 91307 —
Elixir Study Site Westlake Village California — —
Elixir Study Site Pueblo Colorado — —
Elixir Study Site(s) Washington D.C. District of Columbia — —
Elixir Study Site Chiefland Florida 32626 —
Elixir Study Site Coral Gables Florida — —
Elixir Study Site Kissimmee Florida — —
Elixir Study Site(s) Miami Florida — —
Elixir Study Site Saint Cloud Florida — —
Elixir Study Site Winter Park Florida — —
Elixir Study Site Atlanta Georgia 30080 —
Elixir Study Site Austell Georgia — —
Elixir Study Site Perry Georgia — —
Elixir Study Site(s) Chicago Illinois — —
Elixir Study Site Wichita Kansas — —
Elixir Study Site Kansas City Missouri 64132 —
Elixir Study Site St Louis Missouri 63110 —
Elixir Study Site Las Vegas Nevada — —
Elixir Study Site Hamilton New Jersey — —
Elixir Study Site Hillsborough New Jersey — —
Elixir Study Site Sewell New Jersey — —
Elixir Study Site(s) New York New York — —
Elixir Study Site Mooresville North Carolina — —
Elixir Study Site Morehead City North Carolina — —
Elixir Study Site Akron Ohio — —
Elixir Study Site Cincinnati Ohio — —
Elixir Study Site Gallipolis Ohio — —
Elixir Study Site Kettering Ohio — —
Elixir Study Site Medford Oregon — —
Elixir Study Site Harleysville Pennsylvania — —
Elixir Study Site Levittown Pennsylvania — —
Elixir Study Site Uniontown Pennsylvania — —
Elixir Study Site Columbia South Carolina — —
Elixir Study Site Simpsonville South Carolina — —
Elixir Study Site Memphis Tennessee — —
Elixir Study Site Tullahoma Tennessee — —
Elixir Study Site(s) Dallas Texas — —
Elixir Study Site El Paso Texas — —
Elixir Study Site(s) Fort Worth Texas — —
Elixir Study Site(s) Houston Texas — —
Elixir Study Site Humble Texas — —
Elixir Study Site Midland Texas — —
Elixir Study Site New Braunfels Texas — —
Elixir Study Site North Richland Hills Texas — —
Elixir Study Site Pearland Texas — —
Elixir Study Site Plano Texas 75074 —
Elixir Study Site(s) San Antonio Texas — —
Elixir Study Site Temple Texas — —
Elixir Study Site Norfolk Virginia — —
Elixir Study Site Federal Way Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00519142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 17, 2009 · Synced Nov 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00519142 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →